Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Ravulizumab in Adults With Trigger-associated Thrombotic Microangiopathy
2020-005328-13Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in thrombotic microangiopathies (TMA) comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Complete TMA response. Started Mar 2021; status: completed.
02
Drugs
ravulizumab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2020-005328-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005328-13.